CN115304593B - 苯并异噻唑化合物及其药物组合物和应用 - Google Patents
苯并异噻唑化合物及其药物组合物和应用 Download PDFInfo
- Publication number
- CN115304593B CN115304593B CN202211135525.7A CN202211135525A CN115304593B CN 115304593 B CN115304593 B CN 115304593B CN 202211135525 A CN202211135525 A CN 202211135525A CN 115304593 B CN115304593 B CN 115304593B
- Authority
- CN
- China
- Prior art keywords
- compound
- pharmaceutical composition
- benzisothiazole
- premature ejaculation
- dapoxetine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 18
- -1 Benzisothiazole compound Chemical class 0.000 title claims abstract description 14
- 239000003814 drug Substances 0.000 claims abstract description 19
- 150000001875 compounds Chemical class 0.000 claims abstract description 18
- 206010036596 premature ejaculation Diseases 0.000 claims abstract description 17
- 150000003839 salts Chemical class 0.000 claims description 9
- 238000002347 injection Methods 0.000 claims description 4
- 239000007924 injection Substances 0.000 claims description 4
- 239000000203 mixture Substances 0.000 claims description 4
- 238000011282 treatment Methods 0.000 claims description 3
- 239000004480 active ingredient Substances 0.000 claims description 2
- 239000002775 capsule Substances 0.000 claims description 2
- 239000002552 dosage form Substances 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 239000000865 liniment Substances 0.000 claims description 2
- 229940040145 liniment Drugs 0.000 claims description 2
- 239000002674 ointment Substances 0.000 claims description 2
- 239000000843 powder Substances 0.000 claims description 2
- 239000007921 spray Substances 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims 1
- 238000011321 prophylaxis Methods 0.000 claims 1
- USRHYDPUVLEVMC-FQEVSTJZSA-N dapoxetine Chemical compound C1([C@H](CCOC=2C3=CC=CC=C3C=CC=2)N(C)C)=CC=CC=C1 USRHYDPUVLEVMC-FQEVSTJZSA-N 0.000 abstract description 16
- 229960005217 dapoxetine Drugs 0.000 abstract description 14
- 229940079593 drug Drugs 0.000 abstract description 12
- 230000000694 effects Effects 0.000 abstract description 8
- 238000002360 preparation method Methods 0.000 abstract description 5
- 238000001727 in vivo Methods 0.000 abstract description 3
- 238000011160 research Methods 0.000 abstract description 3
- 238000012360 testing method Methods 0.000 abstract description 2
- 210000001625 seminal vesicle Anatomy 0.000 description 19
- 201000010653 vesiculitis Diseases 0.000 description 19
- 241001465754 Metazoa Species 0.000 description 16
- 230000006698 induction Effects 0.000 description 11
- 241000700157 Rattus norvegicus Species 0.000 description 10
- 230000008602 contraction Effects 0.000 description 7
- 238000001543 one-way ANOVA Methods 0.000 description 7
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 241000700159 Rattus Species 0.000 description 4
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 206010067484 Adverse reaction Diseases 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 230000006838 adverse reaction Effects 0.000 description 3
- QRUDEWIWKLJBPS-UHFFFAOYSA-N benzotriazole Chemical group C1=CC=C2N[N][N]C2=C1 QRUDEWIWKLJBPS-UHFFFAOYSA-N 0.000 description 3
- 238000007912 intraperitoneal administration Methods 0.000 description 3
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 238000007619 statistical method Methods 0.000 description 3
- 238000004809 thin layer chromatography Methods 0.000 description 3
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- KXFNMMGBZGXSCJ-UHFFFAOYSA-N ClCCCCN1NNC2=C1C=CC=C2 Chemical compound ClCCCCN1NNC2=C1C=CC=C2 KXFNMMGBZGXSCJ-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 238000000692 Student's t-test Methods 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- 230000006978 adaptation Effects 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000004872 arterial blood pressure Effects 0.000 description 2
- 239000003589 local anesthetic agent Substances 0.000 description 2
- 229960005015 local anesthetics Drugs 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 230000004118 muscle contraction Effects 0.000 description 2
- 229940124834 selective serotonin reuptake inhibitor Drugs 0.000 description 2
- 230000001568 sexual effect Effects 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- NIDSRGCVYOEDFW-UHFFFAOYSA-N 1-bromo-4-chlorobutane Chemical compound ClCCCCBr NIDSRGCVYOEDFW-UHFFFAOYSA-N 0.000 description 1
- JBMKAUGHUNFTOL-UHFFFAOYSA-N Aldoclor Chemical class C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NC=NS2(=O)=O JBMKAUGHUNFTOL-UHFFFAOYSA-N 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- KRDOFMHJLWKXIU-UHFFFAOYSA-N ID11614 Chemical compound C1CNCCN1C1=NSC2=CC=CC=C12 KRDOFMHJLWKXIU-UHFFFAOYSA-N 0.000 description 1
- 206010057672 Male sexual dysfunction Diseases 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000012964 benzotriazole Substances 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- SXDBWCPKPHAZSM-UHFFFAOYSA-M bromate Inorganic materials [O-]Br(=O)=O SXDBWCPKPHAZSM-UHFFFAOYSA-M 0.000 description 1
- SXDBWCPKPHAZSM-UHFFFAOYSA-N bromic acid Chemical compound OBr(=O)=O SXDBWCPKPHAZSM-UHFFFAOYSA-N 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 210000001168 carotid artery common Anatomy 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229940001468 citrate Drugs 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000003205 diastolic effect Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 230000008451 emotion Effects 0.000 description 1
- DZGCGKFAPXFTNM-UHFFFAOYSA-N ethanol;hydron;chloride Chemical compound Cl.CCO DZGCGKFAPXFTNM-UHFFFAOYSA-N 0.000 description 1
- 238000000556 factor analysis Methods 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000012065 filter cake Substances 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 201000001881 impotence Diseases 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 229940049920 malate Drugs 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000003183 myoelectrical effect Effects 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 238000010149 post-hoc-test Methods 0.000 description 1
- 230000003334 potential effect Effects 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 229940001470 psychoactive drug Drugs 0.000 description 1
- 239000004089 psychotropic agent Substances 0.000 description 1
- 238000011552 rat model Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 238000001223 reverse osmosis Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000010898 silica gel chromatography Methods 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 229940086735 succinate Drugs 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 206010042772 syncope Diseases 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- JRMUNVKIHCOMHV-UHFFFAOYSA-M tetrabutylammonium bromide Chemical compound [Br-].CCCC[N+](CCCC)(CCCC)CCCC JRMUNVKIHCOMHV-UHFFFAOYSA-M 0.000 description 1
- 239000003451 thiazide diuretic agent Substances 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
Abstract
苯并异噻唑化合物及其药物组合物和应用,属于医药技术领域,具体涉及一种式(I)所示的新型结构2H‑苯并三氮唑取代的苯并异噻唑化合物,以及包含该化合物的药物组合物和其在制备治疗和/或预防早泄药物中的应用。经体内活性试验研究,该化合物的抗早泄活性明显强于在售药物达泊西汀。
Description
技术领域
本发明属于医药技术领域,具体涉及一种苯并异噻唑化合物及其药物组合物和应用。
背景技术
早泄(Premature ejaculation,早泄)是最常报告的男性性功能障碍之一,全球成年男性早泄发病率为20%~30%,严重影响夫妻感情和家庭和谐。2014年,国际性医学会(The International Society for Sexual Medicine,ISSM)提出了第一个基于证据的原发性早泄的全面定义。目前临床应用的药物主要为达泊西汀、局部麻醉药等,已为早泄的药物治疗开辟了新的道路。但是这些药物存在疗效差、不良反应多、停药率高等问题。达泊西汀是目前全球唯一上市治疗早泄的药物,临床常见不良反应包括恶心、腹泻、头痛、失眠等,也有极低的严重不良反应,如晕厥。达泊西汀临床停药率很高,累积停用率随时间增加。局部麻醉药可通过降低阴茎头的敏感性延迟射精时间,但常见不良反应是可引起阳痿,性满意度较差。
临床医生经常超适应症的使用5-HT再摄取抑制剂(SSRIs)药物,但患者不能突然停药,需在2~3月内逐渐减量,防止SSRIs停药综合征,因此临床使用受限,依从性很低。长期应用精神类药物,患者本身接受性较差。因此研究新的治疗早泄药具有临床意义。
发明内容
针对上述问题,本发明公开一种新型结构2H-苯并三氮唑取代的苯并异噻唑化合物,以及包含该化合物的药物组合物和其在制备治疗或预防早泄药物中的应用。
本发明公开的式(I)所示的苯并异噻唑化合物及其药学上可接受的盐,所述的盐包括盐酸盐、溴氢酸盐、硫酸盐、三氟醋酸盐、甲磺酸盐、酒石酸盐、苹果酸盐、枸橼酸盐、琥珀酸盐等,其盐可含有0.5-3分子的结晶水:
一种药物组合物,包含所述的苯并异噻唑化合物或其在药学上可接受的盐,以及药学上可接受的载体;所述及的载体是指药学领域常规的载体,包括:稀释剂、赋形剂如水;粘合剂如纤维素衍生物、明胶、聚乙烯吡咯烷酮;填充剂如淀粉;崩裂剂如碳酸钙、碳酸氢钠;润滑剂如硬脂酸钙或硬脂酸镁。另外,还可以在所述药物组合物中加入其他辅助剂如香味剂和甜味剂。所述药物组合物在用于口服时,可将其制备成常规的固体制剂如片剂、粉剂、口溶膜剂或胶囊;用于外用时,将其制备成喷雾剂、擦剂、膏剂;用于注射时,可将其制备成注射液。
本发明所述的药物组合物的各种剂型依据本领域常规的方法进行制备,其中活性成分的含量为0.1%~99.5%(重量比)。
本发明所述的苯并异噻唑化合物,或其药学上可接受的盐,或包含所述化合物的药物组合物在制备治疗和/或预防早泄的药物中的应用。
本发明的有益效果:
本发明所述化合物具有显著的抗早泄作用,本品与临床现有唯一批准上市药物达泊西汀相比,具有显著的治疗特点和实质性的技术进步。
本发明所述化合物或其药学上可接受的盐,为一类全新结构的2H-苯并三氮唑取代的苯并异噻唑化合物。经体内活性试验研究,该化合物的抗早泄活性明显强于在售药物达泊西汀。
附图说明
图1:PCA诱导后30min内Wistar大鼠射精总次数柱状图,One-way ANOVA,Dunnettpost hoc,***P<0.001,与PE model组比较,N=5。
图2:PCA诱导后30min内Wistar大鼠初次射精潜伏期柱状图,One-way ANOVA,Dunnett post hoc,*P<0.05,**P<0.01,***P<0.001,与PE model组比较,N=5。
图3:PCA诱导后30min内Wistar大鼠储精囊收缩次数柱状图,One-way ANOVA,Dunnett post hoc,***P<0.001,与PE model组比较,N=5。
图4:PCA诱导后30min内Wistar大鼠初次储精囊收缩潜伏期柱状图,One-wayANOVA,Dunnett post hoc,**P<0.01,***P<0.001,与PE model组比较,N=5。
图5:PCA诱导后30min内Wistar大鼠储精囊基础压力柱状图,One-way ANOVA,Dunnett post hoc,***P<0.001,与PE model组比较,N=5。
图6:PCA诱导后30min内Wistar大鼠储精囊压力峰值柱状图,One-way ANOVA,Dunnett post hoc,***P<0.001,与PE model组比较,N=5。
具体实施方式
试剂和溶剂购自Sigma-Aldrich或Fisher Scientific,无需进一步纯化即可使用。所有反应进行薄层色谱分析(硅胶GF-254薄层板)和LC-MS监测。柱层析纯化使用300-400目硅胶(青岛海洋化工有限公司)。1H和13C NMR光谱记录在Bruker AV-400核磁共振仪测定,以TMS作为内标。通过LC-MS分析确定的化合物纯度大于95%,并同时用于记录化合物的MS光谱。LC-MS分析使用Shimadzu LCMS-2020。
实施例1
(1)关键中间体:1-(4-氯丁基)-2H-苯并三氮唑的制备
苯并三氮唑30.0g(251mmol)、1-溴-4-氯丁烷39.3g(229mmol)、四丁基溴化铵1.85g(6mmol)、氢氧化钠水溶液240g(20%)置于500mL单口瓶中,充分搅拌至物料完全溶解。升温至60℃,搅拌反应2h,TLC监控反应进程。反应完毕后,二氯甲烷240mL×3萃取,无水硫酸钠干燥后减压蒸馏除去溶剂,经硅胶层析柱分离纯化得淡黄色油状液体10.23g(产率19.44%)。
(2)目标化合物的制备
将3-(1-哌嗪基)-1,2-苯并异噻唑1.88g,三乙胺(3.3g)、碘化钾(1.4g)、乙腈15mL加入到50mL单口瓶中,充分搅拌至原料完全溶解。加入1-(4-氯丁基)-2H-苯并三氮唑(1.8g)并升温至81℃回流反应18h。经TLC检测反应结束后,将反应液冷却至室温,抽滤,滤液经减压蒸馏除去溶剂得到黄色油状物。饱和食盐水洗涤,二氯甲烷萃取,减压蒸馏除去溶剂得到油状物,油状物用无水乙醇溶解,加盐酸乙醇溶液调节pH=1,滴毕,室温搅拌1h,析出固体,过滤。滤饼经无水乙醇重结晶得到终产物,记为A001。
经无水乙醇重结晶,得到1.64g白色粉末状固体(产率49%)。1H NMR(400MHz,DMSO-d6)δ10.62(s,1H),8.12(dd,J=11.4,8.2Hz,2H),7.94(dd,J=6.6,3.1Hz,2H),7.63–7.54(m,1H),7.50–7.37(m,3H),4.84(t,J=6.8Hz,2H),4.06(d,J=13.6Hz,2H),3.57(d,J=12.0Hz,2H),3.50–3.39(m,2H),3.32–3.19(m,4H),2.19–2.06(m,2H),1.77(tt,J=6.6,2.5Hz,2H).13C NMR(100MHz,DMSO-d6)δ162.11,152.06,143.63,128.09,126.89,126.31,124.58,123.96,121.14,117.75,55.27,54.86,50.57,46.36,26.50,20.43.LC-MS(ESI)m/z:393.15[M+1]+。
实施例2
化合物A001对早泄模型的体内活性研究
2.1材料与方法
2.1.1化合物信息
2.2实验方案
2.2.1动物信息
2.2.2动物适应
动物到达动物设施后,至少适应性喂养一周。在此期间,对动物健康和是否有任何生理、行为异常进行监测,并将所有出现异常的动物从研究中移除。
2.2.3饲养环境
动物房的环境控制在温度18-26℃,湿度30-70%,并给予12h光照/12h黑暗循环。12h的黑暗周期可能会被暂时中断,以适应研究方案。
2.2.4食物和水
大鼠维持饲料(由江苏省协同医药生物工程有限责任公司提供)以及反渗透水在研究过程中都是随时可用的。
2.2.5动物选择和禁食
本研究中使用的动物是根据动物的健康状况和对笼养的适应能力选择的。实验前,动物不禁食不禁水。
2.2.6动物分组
实验前对动物称取体重,并根据体重进行随机分组,具体如下:
注:p.o.表示口服;i.p.表示腹腔注射;PCA表示对氯苯丙胺盐酸盐。
2.2.7实验步骤:
雄性Wistar大鼠,体重300g左右,适应一周后开始实验。实验当天,使用舒泰5020mg/kg i.p.联合噻拉嗪8mg/kg i.p.麻醉动物后,用保温毯维持体温37℃。暴露颈总动脉用PE50插管以监测实时动脉压力(收缩压、舒张压以及平均动脉压)。暴露动物储精囊及海绵体肌。记录储精囊的压力和海绵体肌电稳定基线10min。达泊西汀组尾静脉给予药物,待测化合物组口服给予待测化合物(PE model组用溶媒代替),1min后诱导PE造模时腹腔注射PCA5mg/kg,继续记录精囊压力图和球海绵体肌EMG变化30min。
实验终点:
A.30min内,动物实际射精次数及第一次射精潜伏期
B.30min内,储精囊收缩的次数,第一次收缩潜伏期,基础压力及峰值压力
2.2.8数据分析
实验数据采用mean±S.E.M.表示,GraphPad Prism 7.0软件进行统计分析。多组间比较采用单因素方差分析(One-way ANOVA),Post hoc test采用Dunnett’t-test进行统计分析;两组间比较采用Student's t-test进行统计分析。P<0.05为具有显著性差异。
2.3结果
表1 PCA诱导后30min内Wistar大鼠各项早泄指标原始数据表
从本研究中得出,Wistar大鼠在PCA诱导后30min内射精次数基本维持约18次,所有剂量组别均较PE model组在射精次数上呈现极为显著的下降(均P<0.05)。低、中、高剂量均优于达泊西汀。(图1)
从初次射精潜伏期结果可得,均较PE model组在初次射精潜伏期时间上呈现极为显著的延长(分别P<0.05,P<0.01,P<0.001)(图2)。此外,PCA诱导后30min内,PE model组大鼠的储精囊收缩次数约为22.4次,储精囊的收缩次数均在6次以下,所有组别均较PE model组在储精囊收缩次数上呈现极为显著的下降(均P<0.05)(图3)2mg/kg剂量下优于达泊西汀。
同时,观察大鼠储精囊初次收缩潜伏期可得,Sham组、达泊西汀组、中剂量组、高剂量组均在初次储精囊收缩潜伏期上较PE model组存在显著的上升(分别P<0.01,P<0.001)(图4)。并且,根据储精囊基础压力监测的数据表明,所有组别均能有效降低PCA诱导后引起的基础储精囊压力(均P<0.001)(图5)。相似的是,储精囊峰值压力监测的数据表明,所有组别均能极为有效降低PCA诱导后引起的峰值储精囊压力(均P<0.001)(图6)。
2.4结论
通过PCA诱导Wistar大鼠早泄模型,监测不同剂量下的本专利受试药物和达泊西汀的潜在效果。从大鼠射精次数、初次射精潜伏期、储精囊压力、海绵体肌肉收缩等相关指标统计分析,揭示达泊西汀和本化合物均能够有效延长射精潜伏期,并且大幅减少射精次数、降低储精囊压力和海绵体肌肉收缩次数。与达泊西汀治疗PE的药效相比,本化合物口服2mg/kg剂量优于盐酸达泊西汀静脉注射剂量2mg/kg。参照达泊西汀生物利用度42%,在相同剂量下,本化合物抗早泄活性显著优于达泊西汀。
Claims (5)
1.一种苯并异噻唑化合物的药学上可接受的盐,其特征在于,所述化合物结构式如下:
。
2.一种药物组合物,其特征在于,包含权利要求1所述的苯并异噻唑化合物的在药学上可接受的盐,以及药学上可接受的载体。
3.根据权利要求2所述的药物组合物,其特征在于,在用于口服时,将药物组合物制备成片剂、口溶膜剂、粉剂、胶囊;用于外用时,将药物组合物制备成喷雾剂、擦剂、膏剂;用于注射时,将药物组合物制备成注射液。
4.根据权利要求2所述的药物组合物,其特征在于,所述的药物组合物的各种剂型中活性成分的含量为0.1%~99.5%。
5.权利要求1所述的苯并异噻唑化合物的药学上可接受的盐在制备治疗和/或预防早泄的药物中的应用。
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202211135525.7A CN115304593B (zh) | 2022-09-19 | 2022-09-19 | 苯并异噻唑化合物及其药物组合物和应用 |
PCT/CN2023/114338 WO2024060911A1 (zh) | 2022-09-19 | 2023-08-23 | 苯并异噻唑化合物及其药物组合物和应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202211135525.7A CN115304593B (zh) | 2022-09-19 | 2022-09-19 | 苯并异噻唑化合物及其药物组合物和应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN115304593A CN115304593A (zh) | 2022-11-08 |
CN115304593B true CN115304593B (zh) | 2024-02-23 |
Family
ID=83866426
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202211135525.7A Active CN115304593B (zh) | 2022-09-19 | 2022-09-19 | 苯并异噻唑化合物及其药物组合物和应用 |
Country Status (2)
Country | Link |
---|---|
CN (1) | CN115304593B (zh) |
WO (1) | WO2024060911A1 (zh) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115304593B (zh) * | 2022-09-19 | 2024-02-23 | 皮摩尔新药(辽宁)有限公司 | 苯并异噻唑化合物及其药物组合物和应用 |
CN115304590A (zh) * | 2022-09-19 | 2022-11-08 | 皮摩尔新药(辽宁)有限公司 | 2h-苯并三氮唑衍生物及其制备方法及含有它们的药物组合物 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101759693A (zh) * | 2008-12-23 | 2010-06-30 | 江苏恩华药业股份有限公司 | 苯骈异恶唑哌啶衍生物及在制备镇痛、镇静药物中的应用 |
WO2014079154A1 (zh) * | 2012-11-26 | 2014-05-30 | 辽宁贝雷生物制药有限公司 | 苯并五元氮杂环基哌啶或哌嗪衍生物及其制备方法和药物组合物 |
CN110478351A (zh) * | 2019-09-29 | 2019-11-22 | 沈阳海王生物技术有限公司 | 多靶标作用化合物x7的新用途 |
CN114209669A (zh) * | 2022-01-28 | 2022-03-22 | 皮摩尔新药(辽宁)有限公司 | 一种缓释制剂及其制备方法与应用 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115381827B (zh) * | 2022-09-19 | 2024-02-06 | 皮摩尔新药(辽宁)有限公司 | 苯骈三氮唑烷基衍生物在制备治疗或预防心血管疾病的药物中的应用 |
CN115304593B (zh) * | 2022-09-19 | 2024-02-23 | 皮摩尔新药(辽宁)有限公司 | 苯并异噻唑化合物及其药物组合物和应用 |
CN115304590A (zh) * | 2022-09-19 | 2022-11-08 | 皮摩尔新药(辽宁)有限公司 | 2h-苯并三氮唑衍生物及其制备方法及含有它们的药物组合物 |
-
2022
- 2022-09-19 CN CN202211135525.7A patent/CN115304593B/zh active Active
-
2023
- 2023-08-23 WO PCT/CN2023/114338 patent/WO2024060911A1/zh unknown
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101759693A (zh) * | 2008-12-23 | 2010-06-30 | 江苏恩华药业股份有限公司 | 苯骈异恶唑哌啶衍生物及在制备镇痛、镇静药物中的应用 |
WO2014079154A1 (zh) * | 2012-11-26 | 2014-05-30 | 辽宁贝雷生物制药有限公司 | 苯并五元氮杂环基哌啶或哌嗪衍生物及其制备方法和药物组合物 |
CN110478351A (zh) * | 2019-09-29 | 2019-11-22 | 沈阳海王生物技术有限公司 | 多靶标作用化合物x7的新用途 |
CN114209669A (zh) * | 2022-01-28 | 2022-03-22 | 皮摩尔新药(辽宁)有限公司 | 一种缓释制剂及其制备方法与应用 |
Non-Patent Citations (1)
Title |
---|
王冠等.N-吲哚烷基哌啶类化合物及其类似物的合成和活性研究.《中国药物化学杂志》.2009,第19卷(第3期),第161-169页. * |
Also Published As
Publication number | Publication date |
---|---|
WO2024060911A1 (zh) | 2024-03-28 |
CN115304593A (zh) | 2022-11-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN115304593B (zh) | 苯并异噻唑化合物及其药物组合物和应用 | |
EP0610595B1 (en) | Composition of l-dopa esters | |
KR20050072809A (ko) | 아세트산 아닐리드 유도체를 유효성분으로 하는 과활동방광 치료제 | |
MXPA05002549A (es) | Cristal para un farmaco oral solido y farmaco oral solido que lo contiene para el tratamiento de la disuria. | |
WO2024060912A1 (zh) | 2h-苯并三氮唑衍生物及其制备方法及含有它们的药物组合物 | |
EP3458448A1 (en) | Methods of using fasn inhibitors | |
NO322309B1 (no) | Indenotiazolforbindelser, legemiddel som inneholder slike forbindelser, fremgangsmate for deres fremstilling og deres anvendelse som anoreksimidler. | |
AU2017287746B2 (en) | Optically active pyranochromenyl phenol derivative and pharmaceutical composition comprising same | |
WO1998027982A1 (fr) | Composition contenant de l'acide ascorbique | |
TWI296522B (en) | Colonic motor dysfunction remedies comprising aminothiazole derivatives as active ingredients | |
RU2056416C1 (ru) | Производные тиомочевины, фармацевтическая композиция и способ лечения | |
HU199440B (en) | Process for producing morpholine derivatives and pharmaceutical compositions comprising the compounds | |
JPH06504541A (ja) | 4−アミノ−3−アシルキノリン誘導体の塩およびその胃酸分泌抑制剤としての使用 | |
JPS62242669A (ja) | ド−パミン−β−ヒドロキシラ−ゼ抑制剤のエステルプロドラツグ | |
JPH033671B2 (zh) | ||
WO2011058943A1 (ja) | Mch r1アンタゴニスト活性を有する化合物とnpy y5受容体アンタゴニスト活性を有する化合物を組み合わせてなる医薬組成物 | |
JP2009051731A (ja) | 新規アスコクロリン誘導体化合物及びそれを含有する医薬組成物 | |
TW201032805A (en) | Pharmaceutical compositions comprising a compound having suppressive effect on nutrient digestion or absorption and a cyclohexanecarboxamide derivative | |
JPH05503510A (ja) | 光学的に純粋な(s)―アテノロールを含む組成物と方法 | |
CN112094255B (zh) | 一种灯盏花乙素苷元衍生物、其制备方法与应用 | |
CN114349665B (zh) | 二甲双胍焦谷氨酸晶体及其制备方法与应用 | |
FR2845385A1 (fr) | Composes derives de la 2-thiohydantoine et leur utilisation en therapeutique | |
US4156009A (en) | Diazepine derivatives | |
WO2010098475A1 (ja) | 摂食障害予防及び治療剤 | |
NZ199008A (en) | 2,3,3a,4,5,6-hexahydro-ih-indolo(3,2,1-de)(1,5)-naphthyridines |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |